Aceclidine, a pupil selective miotic

Aiming to develop new eye care treatments for conditions previously thought to be unachievable

LENZ Therapeutics is committed to delivering scientifically innovative solutions to the eye care space.

Our groundbreaking work has lead to promising advancements toward restoring near vision.

We are eager to continue bringing products to market that are in line with our purpose: to free people to forget about their vision.

Phase 1
Phase 2
Phase 3
US FDA Registration
Phase 1
Phase 2
Phase 3
US FDA Registration
LNZ100 - 1.75% Aceclidine
Presbyopia
Daily Eye Drop Treatment
See results

Aceclidine, known as LNZ100, is in development for the treatment of presbyopia. Presbyopia is the inevitable loss of near vision and impacts 1.8B people globally and 128M people in the US. We aim for an “All Eyes / All Day” eye drop to restore the near vision loss due to presbyopia.

Join our mission

At LENZ Therapeutics, we rise to the occasion with energy and courage to deliver for patients. As a part of our team, you’ll share that innate sense of responsibility to improve the greater good, using your expertise and passion to meaningfully improve lives—because you know you can.

Careers